Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Shares Shorted: Short Interest Down 93.8% in September

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 5,591 shares, a decline of 93.8% from the September 15th total of 90,785 shares. Based on an average daily volume of 21,117 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the company’s stock are sold short.

Cyclacel Pharmaceuticals Trading Up 3.4%

Shares of BGMS stock traded up $0.03 on Friday, hitting $0.85. 14,672 shares of the stock were exchanged, compared to its average volume of 809,095. The firm has a market capitalization of $4.69 million, a P/E ratio of -0.23 and a beta of -0.39. The business has a 50-day moving average of $0.90 and a 200 day moving average of $0.94. Cyclacel Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $6.70.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last announced its earnings results on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $0.34 million during the quarter. Cyclacel Pharmaceuticals had a negative net margin of 118.27% and a negative return on equity of 31.60%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Cyclacel Pharmaceuticals currently has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted medicines for the treatment of cancer. Its research programs center on small-molecule therapies designed to interfere with key cell-cycle and transcription processes involved in tumor growth.

The company’s pipeline has included fadraciclib (CYC065), an oral cyclin-dependent kinase inhibitor being studied for advanced solid tumors and hematologic malignancies. Cyclacel has also developed sapacitabine (CYC682), an oral nucleoside analog, and seliciclib (CYC202), an earlier-stage cyclin-dependent kinase inhibitor.